Skip to main content
Clinical Trials/CTRI/2025/08/092668
CTRI/2025/08/092668
Not yet recruiting
Not Applicable

Visual Field Defects in Parkinson’s Disease: A Cross-Sectional Study on Their Clinical Patterns and Impact on Vision-Related Activities of Daily Living

Dr Priti Singh1 site in 1 country100 target enrollmentStarted: September 10, 2025Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Dr Priti Singh
Enrollment
100
Locations
1
Primary Endpoint
Correlation between visual field defects and disease severity, cognitive function (MoCA), and vision-related quality of life (NEI VFQ-25)

Overview

Brief Summary

This cross-sectional observational study aims to evaluate the prevalence and clinical patterns of visual field defects in individuals diagnosed with Parkinson’s Disease. Visual impairments are increasingly recognized as significant non-motor symptoms of Parkinson’s Disease but are often underdiagnosed in routine clinical practice. The study will use standard visual field testing and cognitive assessments to explore the association between visual deficits, disease severity, and impact on vision-dependent activities of daily living. The hypothesis is that visual field defects are prevalent in Parkinson’s Disease and correlate with disease severity and functional impairment.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
40.00 Year(s) to 99.00 Year(s) (—)
Sex
Female

Inclusion Criteria

  • Diagnosed Parkinson’s Disease (Hoehn and Yahr Stage I–IV) Age above 40 years (to exclude young-onset Parkinson’s Disease) Ability to complete visual field testing and related questionnaires.

Exclusion Criteria

  • Severe cognitive impairment (as per MMSE assessment) Advanced dementia or psychiatric illness interfering with participation Ocular conditions independently causing visual field loss (e.g., advanced glaucoma, retinal dystrophies) Recent ocular surgery within the past 3 months.

Outcomes

Primary Outcomes

Correlation between visual field defects and disease severity, cognitive function (MoCA), and vision-related quality of life (NEI VFQ-25)

Time Frame: At baseline and at 9 months

Secondary Outcomes

  • Identification of visual field defect subtypes using cluster analysis of perimetry data(At the end of data collection phase (Month 6–9))

Investigators

Sponsor
Dr Priti Singh
Sponsor Class
Other [Self Funded ]
Responsible Party
Principal Investigator
Principal Investigator

Dr Priti Singh

All India Institute of Medical Sciences, Bhopal

Study Sites (1)

Loading locations...

Similar Trials